{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:47:37Z","timestamp":1792025257297,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["305659\/2023-5"],"award-info":[{"award-number":["305659\/2023-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["444227\/2025-3"],"award-info":[{"award-number":["444227\/2025-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual\/triple agonists, have revolutionized the management of obesity and type 2 diabetes. However, hair loss has emerged as an adverse event in clinical practice. This review synthesizes the evidence on the prevalence, mechanistic pathways, and clinical course of hair loss associated with semaglutide, tirzepatide, and retatrutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review was conducted using the PubMed\/MEDLINE database. Data were integrated from clinical trials, real-world observational studies, and pharmacovigilance databases to evaluate the oncological and dermatological implications of these therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There is a discrepancy in hair loss prevalence, ranging from 3 to 7% in controlled trials to over 70% in real-world cohorts. Telogen effluvium (TE) is the predominant phenotype, driven primarily by the magnitude and velocity of weight loss rather than drug toxicity. Newer agents like tirzepatide demonstrate stronger associations with hair shedding compared to older GLP-1 RAs. Pharmacovigilance data show inconsistent but significant signals for semaglutide and tirzepatide, with reporting odds ratios indicating a drug-associated risk. Conversely, paradoxical improvements in androgenetic alopecia and inflammatory scarring alopecias have been reported, likely mediated by metabolic normalization and anti-inflammatory effects. Female sex and significant weight reduction (&gt;\u200910%) were the most robust predictors of hair loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Hair loss associated with incretin-based therapies is a biologically complex, threshold-dependent phenomenon reflecting systemic metabolic reprogramming. While predominantly transient and reversible, its psychological impact can compromise treatment adherence. Clinicians should provide proactive counseling, emphasizing the self-limiting nature of TE in this context while monitoring for diverse follicular responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00592-026-02812-3","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:21:47Z","timestamp":1792023707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6381-339X","authenticated-orcid":false,"given":"Ademir Carvalho","family":"Leite J\u00fanior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2431-4779","authenticated-orcid":false,"given":"Howard Lopes","family":"Ribeiro Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"3","key":"2812_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s13300-025-01829-1","volume":"17","author":"JP Miramontes-Gonz\u00e1lez","year":"2026","unstructured":"Miramontes-Gonz\u00e1lez JP, Rodrigo-Ala\u00edz \u00c1, Gabella-Mart\u00edn M, Gonz\u00e1lez-Calle D, Carretero-G\u00f3mez J, Corral-Gudino L (2026) Rewriting diabetes therapy: how incretin modulation is transforming cardiovascular and renal outcomes. Diabetes Ther 17(3):317\u2013330. https:\/\/doi.org\/10.1007\/s13300-025-01829-1","journal-title":"Diabetes Ther"},{"key":"2812_CR2","doi-asserted-by":"publisher","first-page":"9919810","DOI":"10.1155\/jobe\/9919810","volume":"2025","author":"RM Abdelrahman","year":"2025","unstructured":"Abdelrahman RM, Musa TH, Arbab IA, Suliman MH, Ahmed EO, Mohamed AN, Musa HH, Jalal M, Gasmallah SI (2025) Harnessing GLP-1 receptor agonists for obesity treatment: prospects and obstacles on the horizon. J Obes 2025:9919810. https:\/\/doi.org\/10.1155\/jobe\/9919810","journal-title":"J Obes"},{"issue":"8","key":"2812_CR3","doi-asserted-by":"publisher","first-page":"e90021","DOI":"10.7759\/cureus.90021","volume":"17","author":"RF Rojas Lopez","year":"2025","unstructured":"Rojas Lopez RF, Lynett Barrera D, Amaya Mu\u00f1oz MC, Saavedra Diaz MP (2025) Alopecia as an emerging adverse effect associated with glucagon-like peptide-1 (glp-1) receptor agonists for weight loss: a scoping review. Cureus 17(8):e90021. https:\/\/doi.org\/10.7759\/cureus.90021","journal-title":"Cureus"},{"issue":"9","key":"2812_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/biom15091335","volume":"15","author":"W Song","year":"2025","unstructured":"Song W, Peng M, Ma Q, Han X, Gao C, Zhang W, Liu D (2025) The skin microenvironment: a dynamic regulator of hair follicle development, cycling and disease. Biomolecules 15(9):1335. https:\/\/doi.org\/10.3390\/biom15091335","journal-title":"Biomolecules"},{"key":"2812_CR5","doi-asserted-by":"publisher","first-page":"1703423","DOI":"10.3389\/fphar.2025.1703423","volume":"16","author":"H Li","year":"2025","unstructured":"Li H, Wei H, Shentu Q, Cui J, Chen J (2025) Real-world pharmacovigilance insights into drug-induced risk of alopecia. Front Pharmacol 16:1703423. https:\/\/doi.org\/10.3389\/fphar.2025.1703423","journal-title":"Front Pharmacol"},{"issue":"9","key":"2812_CR6","doi-asserted-by":"publisher","first-page":"e92454","DOI":"10.7759\/cureus.92454","volume":"17","author":"OA Alsuwailem","year":"2025","unstructured":"Alsuwailem OA, Alanazi R, Almutairi HM, Asiree RH, Almutairi W, Almutairi TM, Zamandar A, Alkhames S (2025) Hair loss associated with glucagon-like peptide-1 (GLP-1) receptor agonist use: a systematic review. Cureus 17(9):e92454. https:\/\/doi.org\/10.7759\/cureus.92454","journal-title":"Cureus"},{"key":"2812_CR7","doi-asserted-by":"publisher","unstructured":"Alharbi S, Alkhalifah A (2026) Prevalence and predictors of hair shedding among GLP-1 receptor agonist users: a cross-sectional study from Saudi Arabia. Skin Appendage Disord. https:\/\/doi.org\/10.1159\/000550540. Epub ahead of print.","DOI":"10.1159\/000550540."},{"key":"2812_CR8","doi-asserted-by":"publisher","first-page":"548520","DOI":"10.2147\/CCID.S548520","volume":"19","author":"S Umar","year":"2026","unstructured":"Umar S, Tan BH, Shitabata PK (2026) Perifollicular inflammation and fibrosis in androgenetic alopecia: implications for diagnosis and treatment - a comparative histopathologic and clinical study with normal-appearing scalp. Clin Cosmet Investig Dermatol 19:548520","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2812_CR9","doi-asserted-by":"publisher","first-page":"204201882513830","DOI":"10.1177\/20420188251383064","volume":"16","author":"BH Hoteit","year":"2025","unstructured":"Hoteit BH, Kotaich J, Ftouni H, Hazime F, Safawi A, Masri R, Marwani M (2025) The dual impact of GLP-1 receptor agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials. Ther Adv Endocrinol Metab 16:20420188251383064","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2812_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jdin.2026.01.014","volume":"25","author":"SI Vidal","year":"2026","unstructured":"Vidal SI, Akiska YM, Nasseri M, Menta N, Nussbaum D, Cotton CH, Castelo-Soccio L, Friedman A (2026) Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study. JAAD Int 25:133\u2013135","journal-title":"JAAD Int"},{"key":"2812_CR11","doi-asserted-by":"publisher","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","volume":"86","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ (2025) The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine 86:103363. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103363","journal-title":"EClinicalMedicine"},{"issue":"4","key":"2812_CR12","doi-asserted-by":"publisher","first-page":"e70835","DOI":"10.1111\/jocd.70835","volume":"25","author":"Y Argobi","year":"2026","unstructured":"Argobi Y, Jadaan NS, Alshalhoob HB, Alyousef MS, Alotaibi GM, Alwesaibie HS, Alshehri ISM (2026) Predictors and characteristics of hair loss among users of GLP-1 receptor agonists: a cross-sectional analysis. J Cosmet Dermatol 25(4):e70835. https:\/\/doi.org\/10.1111\/jocd.70835","journal-title":"J Cosmet Dermatol"},{"key":"2812_CR13","doi-asserted-by":"publisher","unstructured":"Alharbi S, Alkhalifah A (2026) Prevalence and predictors of hair shedding among GLP-1 receptor agonist users: a cross-sectional study from Saudi Arabia. Skin Appendage Disord. https:\/\/doi.org\/10.1159\/000550540","DOI":"10.1159\/000550540"},{"key":"2812_CR14","doi-asserted-by":"publisher","unstructured":"Herrera HO, Bordeaux JS (2026) Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. J Am Acad Dermatol. Feb 17:S0190-9622(26)00248-3. https:\/\/doi.org\/10.1016\/j.jaad.2026.02.042","DOI":"10.1016\/j.jaad.2026.02.042"},{"issue":"5","key":"2812_CR15","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jaad.2025.01.046","volume":"92","author":"O Burke","year":"2025","unstructured":"Burke O, Sa B, Cespedes DA, Sechi A, Tosti A (2025) Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. J Am Acad Dermatol 92(5):1141\u20131143","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2812_CR16","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.jaad.2025.08.033","volume":"93","author":"Z Neubauer","year":"2025","unstructured":"Neubauer Z, Ong MM, Singal A, Lipner SR (2025) Increased risk of telogen effluvium with tirzepatide compared to other weight loss medications: a retrospective cohort TriNetX database study. J Am Acad Dermatol 93(6):1612\u20131614","journal-title":"J Am Acad Dermatol"},{"key":"2812_CR17","doi-asserted-by":"publisher","unstructured":"Hill MA, Yang AC, Bergfeld W, Piliang M Impact of GLP-1 and GLP-1\/GIP agonists on healthcare resource utilization in individuals with scarring alopecias: A retrospective cohort analysis using TriNetX. J Am Acad Dermatol. 2026:S0190-9622(26)00263-X. https:\/\/doi.org\/10.1016\/j.jaad.2026.02.049","DOI":"10.1016\/j.jaad.2026.02.049"},{"key":"2812_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jdcr.2025.06.012","volume":"63","author":"WS Alzahrani","year":"2025","unstructured":"Alzahrani WS, Bahkali SA, Alharthy RF, Alsabban AS (2025) Alopecia areata following semaglutide treatment for weight loss: a case report. JAAD Case Rep 63:44\u201346. https:\/\/doi.org\/10.1016\/j.jdcr.2025.06.012","journal-title":"JAAD Case Rep"},{"issue":"6","key":"2812_CR19","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s10557-024-07613-w","volume":"39","author":"M Nakhla","year":"2025","unstructured":"Nakhla M, Nair A, Balani P, Ujjawal A, Arun Kumar P, Dasari M, Yukselen Z, Bansal K, Ganatra S, Dani SS (2025) Risk of suicide, hair loss, and aspiration with GLP1-receptor agonists and other diabetic agents: a real-world pharmacovigilance study. Cardiovasc Drugs Ther 39(6):1331\u20131341. https:\/\/doi.org\/10.1007\/s10557-024-07613-w","journal-title":"Cardiovasc Drugs Ther"},{"key":"2812_CR20","doi-asserted-by":"publisher","unstructured":"Daniel S, Waggett S, Lyles E, Sagut P, Shamaei Zadeh P, Marcelletti A, Stegura C, Wine Lee L (2025) A retrospective comparative analysis of cutaneous adverse reactions in GLP-1 agonist therapies. J Drugs Dermatol. ;24(4):413\u2013415. https:\/\/doi.org\/10.36849\/JDD.8605","DOI":"10.36849\/JDD.8605"},{"issue":"6","key":"2812_CR21","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1111\/dom.16376","volume":"27","author":"TH Kim","year":"2025","unstructured":"Kim TH, Lee K, Park S, Oh J, Park J, Jo H, Lee H, Cho J, Wen X, Cho H, Kim S, Yon DK (2025) Adverse drug reaction patterns of GLP-1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database. Diabetes Obes Metab 27(6):3490\u20133502. https:\/\/doi.org\/10.1111\/dom.16376","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2812_CR22","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1111\/jdv.20197","volume":"39","author":"H Godfrey","year":"2025","unstructured":"Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R (2025) Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol 39(2):e153\u2013e154. https:\/\/doi.org\/10.1111\/jdv.20197","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2812_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jdcr.2024.06.001","volume":"50","author":"ER Gordon","year":"2024","unstructured":"Gordon ER, Musleh S, Bordone LA (2024) Treatment of insulin resistance with tirzepatide leading to improvement of hair loss. JAAD Case Rep 50:123\u2013125. https:\/\/doi.org\/10.1016\/j.jdcr.2024.06.001","journal-title":"JAAD Case Rep"},{"issue":"12","key":"2812_CR24","doi-asserted-by":"publisher","first-page":"e76267","DOI":"10.7759\/cureus.76267","volume":"16","author":"K Morrissette","year":"2024","unstructured":"Morrissette K, Hansen S, Pavlis M, Murray JC (2024) Improvement of recalcitrant folliculitis decalvans with tirzepatide: a case report. Cureus 16(12):e76267. https:\/\/doi.org\/10.7759\/cureus.76267","journal-title":"Cureus"},{"key":"2812_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jdin.2026.01.014","volume":"25","author":"SI Vidal","year":"2026","unstructured":"Vidal SI, Akiska YM, Nasseri M, Menta N, Nussbaum D, Cotton CH, Castelo-Soccio L, Friedman A (2026) Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study. JAAD Int 25:133\u2013135","journal-title":"JAAD Int"},{"issue":"5","key":"2812_CR26","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.3390\/ijms25052542","volume":"25","author":"R Cuevas-Diaz Duran","year":"2024","unstructured":"Cuevas-Diaz Duran R, Martinez-Ledesma E, Garcia-Garcia M, Bajo Gauzin D, Sarro-Ram\u00edrez A, Gonzalez-Carrillo C, Rodr\u00edguez-Sardin D, Fuentes A, Cardenas-Lopez A (2024) The biology and genomics of human hair follicles: a focus on androgenetic alopecia. Int J Mol Sci 25(5):2542. https:\/\/doi.org\/10.3390\/ijms25052542","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2812_CR27","doi-asserted-by":"publisher","first-page":"e32726","DOI":"10.7759\/cureus.32726","volume":"14","author":"R Hasan","year":"2022","unstructured":"Hasan R, Juma H, Eid FA, Alaswad HA, Ali WM, Aladraj FJ (2022) Effects of hormones and endocrine disorders on hair growth. Cureus 14(12):e32726. https:\/\/doi.org\/10.7759\/cureus.32726","journal-title":"Cureus"},{"key":"2812_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-026-01021-6","author":"S Seyed Jafari","year":"2026","unstructured":"Seyed Jafari S, Caro G, Lipner SR et al (2026) The impact of GLP-1 receptor agonists on hair: beneficial effects or adverse outcomes? Am J Clin Dermatol. https:\/\/doi.org\/10.1007\/s40257-026-01021-6","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"2812_CR29","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/ijd.70133","volume":"65","author":"MK Branyiczky","year":"2026","unstructured":"Branyiczky MK, Lowe MS, McMullen E, Donovan J, Khosravi-Hafshejani T (2026) Effects of GLP-1 receptor agonists on hair loss and regrowth: a systematic review. Int J Dermatol 65(5):1030\u20131032. https:\/\/doi.org\/10.1111\/ijd.70133","journal-title":"Int J Dermatol"},{"issue":"3","key":"2812_CR30","doi-asserted-by":"publisher","first-page":"e70125","DOI":"10.1111\/jocd.70125","volume":"24","author":"D Haykal","year":"2025","unstructured":"Haykal D (2025) Alopecia and semaglutide: connecting the dots for patient safety. J Cosmet Dermatol 24(3):e70125. https:\/\/doi.org\/10.1111\/jocd.70125","journal-title":"J Cosmet Dermatol"},{"issue":"4","key":"2812_CR31","doi-asserted-by":"publisher","first-page":"e70163","DOI":"10.1002\/dmrr.70163","volume":"42","author":"N Lee","year":"2026","unstructured":"Lee N, Kim Y, Not All (2026) GLP-1 receptor agonists are alike: real-world evidence of differential endocrine and dermatologic safety. Diabetes Metab Res Rev 42(4):e70163. https:\/\/doi.org\/10.1002\/dmrr.70163","journal-title":"Diabetes Metab Res Rev"},{"key":"2812_CR32","doi-asserted-by":"publisher","first-page":"bjhh38","DOI":"10.62742\/2965-7911.2026.3.bjhh38","volume":"3","author":"AC Leite","year":"2026","unstructured":"Leite AC, Leite AC Jr (2026) Telogen effluvium and metabolic stress in modern weight loss inter-ventions: a narrative clinical review. Brazilian J Hair Health 3:bjhh38","journal-title":"Brazilian J Hair Health"},{"issue":"2 Suppl 3","key":"2812_CR33","doi-asserted-by":"publisher","first-page":"E228","DOI":"10.15167\/2421-4248\/jpmh2022.63.2S3.2765","volume":"63","author":"N Gokce","year":"2022","unstructured":"Gokce N, Basgoz N, Kenanoglu S, Akalin H, Ozkul Y, Ergoren MC, Beccari T, Bertelli M, Dundar M (2022) An overview of the genetic aspects of hair loss and its connection with nutrition. J Prev Med Hyg 63(2 Suppl 3):E228\u2013E238. https:\/\/doi.org\/10.15167\/2421-4248\/jpmh2022.63.2S3.2765","journal-title":"J Prev Med Hyg"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02812-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-026-02812-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-026-02812-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:21:48Z","timestamp":1792023708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-026-02812-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":33,"alternative-id":["2812"],"URL":"https:\/\/doi.org\/10.1007\/s00592-026-02812-3","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"7 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declares that they have no conflicts of interest. All authors conceived and wrote the study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}